Ipilimumab plus nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab plus nivolumab in advanced non-clear cell renal cell carcinoma.

被引：0
|
作者：
Gedye, Craig
Pook, David William
Krieger, Laurence Eliot Miles
Harris, Carole A.
Goh, Jeffrey C.
Kichenadasse, Ganessan
Gurney, Howard
Underhill, Craig
Parnis, Francis
Joshua, Anthony M.
Ferguson, Tom
Roncolato, Felicia
Harrison, Michelle L.
Begbie, Stephen
Morris, Michelle Frances
Hovey, Elizabeth J.
George, Mathew
Prithviraj, Prashanth
Link, Emma
Davis, Ian D.
机构：
[1] Calvary Mater Newcastle, Waratah, NSW, Australia
[2] Monash Univ, Melbourne, Vic, Australia
[3] Royal North Shore Hosp, Northern Canc Inst, St Leonards, NSW, Australia
[4] St George Hosp Canc Care Ctr, Kingsford, NSW, Australia
[5] Royal Brisbane & Womens Hosp, Herston, Qld, Australia
[6] Univ Queensland, St Lucia, Qld, Australia
[7] Southern Oncol Clin Res Unit, Bedford Pk, SA, Australia
[8] Macquarie Univ, Dept Clin Med, Sydney, NSW, Australia
[9] UNSW Rural Med Sch, Albury Campus, Albury, NSW, Australia
[10] Ashford Canc Ctr, Adelaide, SA, Australia
[11] St Vincents Hosp, Sydney, NSW, Australia
[12] Royal Perth Hosp, Perth, WA, Australia
[13] Macarthur Canc Therapy Ctr, Sydney, NSW, Australia
[14] Royal Prince Alfred Hosp, Hunters Hill, NSW, Australia
[15] Port Macquarie Base Hosp, Port Macquarie, Australia
[16] Sunshine Coast Canc Serv, Nambour, Australia
[17] Prince Wales Hosp, Sydney, NSW, Australia
[18] Northwest Canc Ctr, North Tamworth, Australia
[19] Ballarat Oncol & Haematol Serv, Ballarat, Vic, Australia
[20] Peter MacCallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
[21] Monash Univ, Eastern Hlth Clin Sch, Box Hill, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4565
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4565
引用
收藏
页数：3
相关论文
共 50 条
  • [1] UNISON - nivolumab then ipilimumab plus nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1-Nivolumab monotherapy.
    Gedye, Craig
    Pook, David William
    Krieger, Laurence Eliot Miles
    Harris, Carole A.
    Goh, Jeffrey C.
    Kichenadasse, Ganessan
    Gurney, Howard
    Underhill, Craig
    Parnis, Francis
    Joshua, Anthony M.
    Ferguson, Tom
    Roncolato, Felicia
    Harrison, Michelle L.
    Begbie, Stephen
    Morris, Michelle Frances
    Hovey, Elizabeth J.
    George, Mathew
    Prithviraj, Prashanth
    Liow, Elizabeth Chien Hern
    Davis, Ian D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [2] UNISON: Nivolumab then ipilimumab plus nivolumab in advanced nonclear cell renal cell carcinoma (ANZUP 1602)
    Gedye, Craig
    Pook, David William
    Krieger, Laurence Eliot Miles
    Harris, Carole A.
    Goh, Jeffrey C.
    Kichenadasse, Ganessan
    Gurney, Howard
    Underhill, Craig
    Parnis, Francis
    Joshua, Anthony M.
    Ferguson, Thomas
    Roncolato, Felicia
    Harrison, Michelle L.
    Morris, Michelle Frances
    Begbie, Stephen
    Hovey, Elizabeth J.
    George, Mathew
    Prithviraj, Prashanth
    Liow, Elizabeth Chien Hern
    Davis, Ian D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [3] Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab plus nivolumab in advanced nonclear cell renal cell carcinoma.
    Conduit, Ciara
    Kichenadasse, Ganessan
    Harris, Carole A.
    Gurney, Howard
    Ferguson, Tom
    Parnis, Francis
    Goh, Jeffrey C.
    Morris, Michelle Frances
    Underhill, Craig
    Pook, David William
    Davis, Ian D.
    Roncolato, Felicia
    Harrison, Michelle L.
    Begbie, Stephen
    Joshua, Anthony M.
    Link, Emma
    Hovey, Elizabeth J.
    Gedye, Craig
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Nivolumab plus ipilimumab in advanced renal-cell carcinoma
    Gunjur, Ashray
    [J]. LANCET ONCOLOGY, 2018, 19 (05): : E232 - E232
  • [5] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
    Cerrato, Clara
    Pradere, Benjamin
    Mir, Maria Carmen
    [J]. EUROPEAN UROLOGY, 2023, 84 (04) : E93 - E93
  • [6] Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma
    Bando, Yukari
    Furukawa, Junya
    Okamura, Yasuyoshi
    Hara, Takuto
    Terakawa, Tomoaki
    Nakano, Yuzo
    Fujisawa, Masato
    [J]. ANTICANCER RESEARCH, 2022, 42 (02) : 973 - 979
  • [7] FDA Approves Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma
    Schuyler, Devon
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (05) : 387 - 387
  • [8] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    Choueiri, Toni K.
    Powles, Thomas
    Albiges, Laurence
    Burotto, Mauricio
    Szczylik, Cezary
    Zurawski, Bogdan
    Ruiz, Eduardo Yanez
    Maruzzo, Marco
    Zaizar, Alberto Suarez
    Fein, Luis E.
    Schutz, Fabio A.
    Heng, Daniel Y. C.
    Wang, Fong
    Mataveli, Fabio
    Chang, Yu-Lin
    van Kooten Losio, Maximiliano
    Suarez, Cristina
    Motzer, Robert J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (19): : 1767 - 1778
  • [9] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    Gervaso, Lorenzo
    Fazio, Nicola
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (05): : 476 - 477
  • [10] Nivolumab and Ipilimumab in Renal Cell Carcinoma
    Alakus, Hakan
    Zander, Thomas
    Bruns, Christiane
    [J]. ONKOLOGE, 2018, 24 (06): : 500 - 504
12345